← Back to Investors

Medicxi

Medicxi is a leading European life sciences venture capital firm founded by former partners of Index Ventures. They specialize in therapeutics investments, focusing on companies with innovative science and strong potential for clinical and commercial success.

Location
London, United Kingdom
Founded
2016
AUM
€800M+
Investment Range
€5M - €50M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c

Investment Thesis

Medicxi invests in innovative therapeutics companies with transformative potential. They focus on companies with differentiated science, experienced management teams, and clear clinical development strategies. Their deep scientific expertise allows them to identify and support breakthrough opportunities.

Team

Partners / Managing Directors (Health & Bio Focus)

  • Francesco De Rubertis, PhD - Partner
  • Kevin Johnson - Partner
  • David Grainger, PhD - Partner
  • Michèle Ollier - Partner

Other Key Team Members

  • Science-driven investment team

Focus Areas

  • Therapeutics (oncology, immunology, rare diseases)
  • Drug discovery
  • Novel modalities
  • European biotech
  • Company creation
  • Platform technologies

Notable Exits

  • Novimmune - Acquired by Aptinyx and others
  • Amryt Pharma - IPO (rare diseases)
  • Strong track record of biotech exits through M&A and IPOs

Sources